JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on December 1, 2000
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
275/49/38921    most recent
M004691200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scheidegger, K. J.
Right arrow Articles by Delafontaine, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheidegger, K. J.
Right arrow Articles by Delafontaine, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print September 11, 2000
J. Biol. Chem, 10.1074/jbc.M004691200
Submitted on May 31, 2000
Revised on August 22, 2000
Accepted on September 11, 2000

Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells: Mechanisms for its atheroprotective effects

Kathrin J. Scheidegger, Bruno Cenni, Didier Picard, and Patrick Delafontaine

Division of Cardiology, University Hospital of Geneva, 1211, Geneva 14

Corresponding Author: patrice.delafontaine{at}hcuge.ch

Insulin-like growth factor (IGF-1) is a potent mitogen for vascular smooth muscle cells. Both IGF-1 and its receptor have been shown to be highly expressed in atherosclerotic lesions. Here we investigated whether part of the vasculoprotective properties of E2 may be mediated by its negative regulation of the IGF-1 system. HeLa cells which do not contain endogenous estrogen receptors (ER) were transiently transfected with IGF-1R promoter constructs with or without a plasmid encoding human ER or ER and treated with 100 nM 17-estradiol (E2) for 24 h. E2 treatment decreased basal luciferase activity by 51% and this effect was dependent on co-expression of ER, whereas no repression was observed with ER. A mutation within the DNA binding domain of the ER abolished the repressor function of the ER receptor. Similarly, E2 decreased IGF-1R transcription by 21% in rat aortic smooth muscle cells (RASMC) which express endogenous ER. This effect was specific for E2, since it was inhibited by an antiestrogen and since progesterone did not have any effect on IGF-1R expression in HeLa or RASMC transfected with progesterone receptor. Accordingly, E2 decreased IGF-1R and IGF-1 mRNA in RASMC by 47% and 33%. Western blot analysis and radioligand binding studies showed that E2 also dose-dependently decreased IGF-1R protein expression in RASMC by 70% and 30%, respectively, and that IGF-1 protein was reduced by 43%. Repression of IGF-1R promoter activity by a combination of ER and E2 did not appear to be mediated via direct binding of ER to the IGF-1R promoter but rather by inhibition of SP1 binding to the IGF-1R promoter. Thus, E2 downregulates IGF-1R and IGF-1 expression in vascular smooth muscle cells. This may have important implications for the understanding of the beneficial effects of estrogen in the cardiovascular system.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
J. Kawagoe, M. Ohmichi, S. Tsutsumi, T. Ohta, K. Takahashi, and H. Kurachi
Mechanism of the Divergent Effects of Estrogen on the Cell Proliferation of Human Umbilical Endothelial Versus Aortic Smooth Muscle Cells
Endocrinology, December 1, 2007; 148(12): 6092 - 6099.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Bonnefont, L. Daulhac, M. Etienne, E. Chapuy, C. Mallet, L. Ouchchane, C. Deval, J.-P. Courade, M. Ferrara, A. Eschalier, et al.
Acetaminophen Recruits Spinal p42/p44 MAPKs and GH/IGF-1 Receptors to Produce Analgesia via the Serotonergic System
Mol. Pharmacol., February 1, 2007; 71(2): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
S. Maor, D. Mayer, R. I Yarden, A. V Lee, R. Sarfstein, H. Werner, and M. Z Papa
Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1
J. Endocrinol., December 1, 2006; 191(3): 605 - 612.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. J. Elliot, M. Karl, M. Berho, X. Xia, S. Pereria-Simon, D. Espinosa-Heidmann, and G. E. Striker
Smoking Induces Glomerulosclerosis in Aging Estrogen-Deficient Mice through Cross-Talk between TGF-beta1 and IGF-I Signaling Pathways
J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3315 - 3324.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Matuszewska, D. Kuczynska-Wisnik, E. Laskowska, and K. Liberek
The Small Heat Shock Protein IbpA of Escherichia coli Cooperates with IbpB in Stabilization of Thermally Aggregated Proteins in a Disaggregation Competent State
J. Biol. Chem., April 1, 2005; 280(13): 12292 - 12298.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot
Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells
Endocrinology, February 1, 2005; 146(2): 889 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Delafontaine, Y.-H. Song, and Y. Li
Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels
Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 435 - 444.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
C. K. Cheng, B. K. C. Chow, and P. C. K. Leung
An Activator Protein 1-Like Motif Mediates 17{beta}-Estradiol Repression of Gonadotropin-Releasing Hormone Receptor Promoter via an Estrogen Receptor {alpha}-Dependent Mechanism in Ovarian and Breast Cancer Cells
Mol. Endocrinol., December 1, 2003; 17(12): 2613 - 2629.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Zaina, L. Pettersson, A. B. Thomsen, C.-M. Chai, Z. Qi, J. Thyberg, and J. Nilsson
Shortened Life Span, Bradycardia, and Hypotension in Mice with Targeted Expression of an Igf2 Transgene in Smooth Muscle Cells
Endocrinology, June 1, 2003; 144(6): 2695 - 2703.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Kressler, S. N. Schreiber, D. Knutti, and A. Kralli
The PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor alpha
J. Biol. Chem., April 12, 2002; 277(16): 13918 - 13925.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. V. Sharma, M. V. Gurjar, and R. C. Bhalla
Genome and Hormones: Gender Differences in Physiology: Selected Contribution: Estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappa B activation in VSM cells from female rats
J Appl Physiol, November 1, 2001; 91(5): 2400 - 2406.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.